• Explore /
  • Poster
  • / The BRIGHTER trial: A phase III randomized double-blind study of BBI-608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma.

The BRIGHTER trial: A phase III randomized double-blind study of BBI-608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma.

Abstract Poster

Authors

Manish Shah

Manish A. Shah

Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY

Manish A. Shah , Kei Muro , Kohei Shitara , Niall C. Tebbutt , Yung-Jue Bang , Florian Lordick , Laura Borodyansky , Chiang Li

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT02178956

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS4144)

DOI

10.1200/JCO.2016.34.15_suppl.TPS4144

Abstract #

TPS4144

Poster Bd #

129b

Abstract Disclosures

Similar Posters

First Author: Manish A. Shah

First Author: Manish A. Shah

First Author: Kei Muro

First Author: Nick Pavlakis